Minimally Invasive Evacuation for Spontaneous Supratentorial Intracerebral Hemorrhage After Contemporary Randomized Trials: Patient Selection, Timing, and Platform Choice
Therapeutics and Clinical Risk Management · 2026-07 · Volume 22 · 1-19
DOI: 10.2147/tcrm.s619414 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutics and Clinical Risk Management, 2026-07. Verfasst von Xin Shao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Spontaneous intracerebral hemorrhage (ICH) accounts for only 10-15% of all strokes but contributes disproportionately to stroke-related death and long-term disability. For decades, surgical evacuation of supratentorial ICH failed to show consistent functional benefit in randomized trials. The Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH) trial altered this trajectory by providing the first positive randomized evidence that an early, protocolized minimally invasive parafascicular approach can improve utility-weighted 180-day outcome in a predominantly lobar population. Interpretation was complicated by the 2025 MIND trial, which tested Artemis-based minimally invasive evacuation in a cohort dominated by deep hemorrhage and, after early termination, did not show benefit on its primary endpoint. In parallel, the SWITCH trial suggested at most a limited role for decompressive craniectomy without clot evacuation in severe deep ICH, with any possible reduction in death or extreme disability tempered by substantial residual disability among survivors. These trials indicate that the current issue is no longer the general rationale for surgery, but the specific patients, treatment window, and technical conditions under which evacuation is most likely to confer net benefit. This review traces the evidence from the International Surgical Trial in Intracerebral Haemorrhage (STICH) program and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE) program to ENRICH and MIND, compares the major minimally invasive strategies, and examines hemorrhage location, hematoma volume, and treatment timing as the principal determinants of patient selection. On the basis of current randomized evidence, the clearest evidence-supported indication is early (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
- Department of Endocrinology and Metabolism, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
- Department of Cardiac Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Zitieren
APA
Shao, X., Tan, C., Yu, M., & Yang, F. (2026). Minimally Invasive Evacuation for Spontaneous Supratentorial Intracerebral Hemorrhage After Contemporary Randomized Trials: Patient Selection, Timing, and Platform Choice. Therapeutics and Clinical Risk Management, Volume 22, 1-19. https://doi.org/10.2147/tcrm.s619414
Vancouver
Shao X, Tan C, Yu M, Yang F. Minimally Invasive Evacuation for Spontaneous Supratentorial Intracerebral Hemorrhage After Contemporary Randomized Trials: Patient Selection, Timing, and Platform Choice. Therapeutics and Clinical Risk Management. 2026;Volume 22:1-19. doi:10.2147/tcrm.s619414
BibTeX
@article{Shao2026,
author = {Shao, Xin and Tan, Chen and Yu, Meiqi and Yang, Fan},
title = {Minimally Invasive Evacuation for Spontaneous Supratentorial Intracerebral Hemorrhage After Contemporary Randomized Trials: Patient Selection, Timing, and Platform Choice},
journal = {Therapeutics and Clinical Risk Management},
year = {2026},
volume = {Volume 22},
pages = {1--19},
doi = {10.2147/tcrm.s619414}
}
EUVIMED